Testing the drug mirdametinib for brain and spinal cord tumors
Official title: A Study of Mirdametinib in People With Central Nervous System Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called mirdametinib in people with tumors of the brain and spinal cord.
Read our full plain-language summary
What the trial team says
The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Key facts
- Registry number
- NCT07539441
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Central Nervous System Tumors, Glioma
Where it is running
This trial lists 7 sites.
-
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) (Basking Ridge)
- Memorial Sloan Kettering Monmouth (Limited protocol activities) (Middletown)
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) (Montvale)
-
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) (Commack)
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) (Harrison)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) (New York)
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) (Rockville Centre)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.